TriangleNCT00245037 · STUDY IN CONTEXT
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
Read the full study record and all posted results →
Linked outcomes
Non-hematologic toxicities and adverse experiences ≥ Grade 3 occurrences measured up to day +100 using the NCI Common Toxicity Criteria for Adverse Events v3.0 (CTCAE). Infections and GVHD will be assessed up to 5 years post transplant. The following data represents the number of regimen-related, grade 3 and 4 toxicities that occurred in each category.
Percent of subjects with non-relapse mortality two years after conditioning with busulfan with fludarabine/200 cGy TBI in patients with hematologic malignancies at moderate to high risk for graft rejection and/or relapse of underlying disease.
The percentage of overall patient survival (out of 147 participants) for Years 1, 2, 3 and 5.
The percentage of progression-free patients (out of 147 participants) at Years 1, 2, 3, and 5. Definition of Disease Progression: MM/Plasma Cell: Increasing bone pain or increase in serum/urine monoclonal protein by 25%. CLL/NHL/HD: New sites of lymphadenopathy; ≥ 25% increase in lymph node size; Blood or bone marrow involvement with clonal B-cells; Increase of ≥ 25% bone marrow involvement; ≥ 25% increase in blood involvement with clonal B-cells. AML/ALL: Any incidence of relapse (\>5% blasts) by evaluation of the bone marrow aspirate. CML: Inability to control platelet or granulocyte counts; Increase in baseline number of metaphases demonstrating the Ph+ chromosome by \>25%; Any other new cytogenetic abnormality; Transformation to accelerated phase or blast crisis. MDS/MPD: Any evidence by morphologic or flow cytometric evaluation of the bone marrow aspirate of new blasts (\>5%) or worsening cytopenia or cytogenetic evidence of recurrence.
The percentage of patients (out of 147 participants) who relapsed at Years 1 and 2. Relapse is defined as the presence of \>5% blasts by morphology on a post-transplant bone marrow aspirate.
Grading of Acute GVHD: Severity of Individual Organ Involvement: Skin * 1 a maculopapular eruption involving less than 25% of the body surface * 2 a maculopapular eruption involving 25-50% of the body surface * 3 generalized erythroderma * 4 generalized erythroderma with bullous formation and/or with desquamation Liver * 1 bilirubin 2.0-3.0mg/100mL * 2 bilirubin 3-5.9mg/100mL * 3 bilirubin 6-14.9mg/100mL * 4 bilirubin \>15mg/100mL Gut Diarrhea is graded +1 to +4 in severity. Nausea/vomiting and/or anorexia caused by GVHD is assigned as +1 in severity Diarrhea * 1 \<1000mL of liquid stool/day * 2 \>1,000mL of stool/day * 3 \>1,500mL of stool/day * 4 2,000mL of stool/day, severe abdominal pain, with or without ileus Severity of GVHD: Grade 1 +1 to +2 skin rash; No gut or liver involvement Grade 2 +1 to +3 skin rash;+1 GI involvement and/or +1 liver
Reported safety
Quality of life and patient-reported measures
No linked quality-of-life measure is recorded for this setting and study.
Full draft applicability and source-link record
- trial
- release id
- clinical-indications-draft-1
- disease state id
- ds-myeloproliferative-neoplasms
- nct id
- NCT00245037
- trial label
- Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
- applicability
- narrower
- applicability note
- Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- provenance class
- registry-condition-search
- discovery note
- Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
- outcome Count
- 6
- harms Count
- 1
- qol Count
- 0
- outcomes
- release id
- clinical-indications-draft-1
- disease state id
- ds-myeloproliferative-neoplasms
- nct id
- NCT00245037
- outcome key
- om-0000
- source section id
- NCT00245037-om-0000
- source outcome index
- 0
- endpoint
- Regimen-Related Toxicities
- endpoint definition
- Non-hematologic toxicities and adverse experiences ≥ Grade 3 occurrences measured up to day +100 using the NCI Common Toxicity Criteria for Adverse Events v3.0 (CTCAE). Infections and GVHD will be assessed up to 5 years post transplant. The following data represents the number of regimen-related, grade 3 and 4 toxicities that occurred in each category.
- time origin
- 5 years post-transplant
- analysis role
- primary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-myeloproliferative-neoplasms
- nct id
- NCT00245037
- outcome key
- om-0001
- source section id
- NCT00245037-om-0001
- source outcome index
- 1
- endpoint
- Non-relapse Mortality
- endpoint definition
- Percent of subjects with non-relapse mortality two years after conditioning with busulfan with fludarabine/200 cGy TBI in patients with hematologic malignancies at moderate to high risk for graft rejection and/or relapse of underlying disease.
- time origin
- Two years post-transplant
- analysis role
- primary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-myeloproliferative-neoplasms
- nct id
- NCT00245037
- outcome key
- om-0002
- source section id
- NCT00245037-om-0002
- source outcome index
- 2
- endpoint
- Overall Survival
- endpoint definition
- The percentage of overall patient survival (out of 147 participants) for Years 1, 2, 3 and 5.
- time origin
- Years 1, 2, 3 and 5
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-myeloproliferative-neoplasms
- nct id
- NCT00245037
- outcome key
- om-0003
- source section id
- NCT00245037-om-0003
- source outcome index
- 3
- endpoint
- Progression-Free Survival
- endpoint definition
- The percentage of progression-free patients (out of 147 participants) at Years 1, 2, 3, and 5. Definition of Disease Progression: MM/Plasma Cell: Increasing bone pain or increase in serum/urine monoclonal protein by 25%. CLL/NHL/HD: New sites of lymphadenopathy; ≥ 25% increase in lymph node size; Blood or bone marrow involvement with clonal B-cells; Increase of ≥ 25% bone marrow involvement; ≥ 25% increase in blood involvement with clonal B-cells. AML/ALL: Any incidence of relapse (\>5% blasts) by evaluation of the bone marrow aspirate. CML: Inability to control platelet or granulocyte counts; Increase in baseline number of metaphases demonstrating the Ph+ chromosome by \>25%; Any other new cytogenetic abnormality; Transformation to accelerated phase or blast crisis. MDS/MPD: Any evidence by morphologic or flow cytometric evaluation of the bone marrow aspirate of new blasts (\>5%) or worsening cytopenia or cytogenetic evidence of recurrence.
- time origin
- Years 1, 2, 3, and 5
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-myeloproliferative-neoplasms
- nct id
- NCT00245037
- outcome key
- om-0004
- source section id
- NCT00245037-om-0004
- source outcome index
- 4
- endpoint
- Relapse Mortality
- endpoint definition
- The percentage of patients (out of 147 participants) who relapsed at Years 1 and 2. Relapse is defined as the presence of \>5% blasts by morphology on a post-transplant bone marrow aspirate.
- time origin
- Years 1 and 2
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-myeloproliferative-neoplasms
- nct id
- NCT00245037
- outcome key
- om-0005
- source section id
- NCT00245037-om-0005
- source outcome index
- 5
- endpoint
- Acute Graft-Versus-Host Disease (aGVHD) Outcome
- endpoint definition
- Grading of Acute GVHD: Severity of Individual Organ Involvement: Skin * 1 a maculopapular eruption involving less than 25% of the body surface * 2 a maculopapular eruption involving 25-50% of the body surface * 3 generalized erythroderma * 4 generalized erythroderma with bullous formation and/or with desquamation Liver * 1 bilirubin 2.0-3.0mg/100mL * 2 bilirubin 3-5.9mg/100mL * 3 bilirubin 6-14.9mg/100mL * 4 bilirubin \>15mg/100mL Gut Diarrhea is graded +1 to +4 in severity. Nausea/vomiting and/or anorexia caused by GVHD is assigned as +1 in severity Diarrhea * 1 \<1000mL of liquid stool/day * 2 \>1,000mL of stool/day * 3 \>1,500mL of stool/day * 4 2,000mL of stool/day, severe abdominal pain, with or without ileus Severity of GVHD: Grade 1 +1 to +2 skin rash; No gut or liver involvement Grade 2 +1 to +3 skin rash;+1 GI involvement and/or +1 liver
- time origin
- Day 100, Month 6
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- This is cumulative incidence of grades 2-4 aGVHD at 100 days and at 6 months. Out of the total number of participants, grades 2-4 aGVHD occurred in 79 patients.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- arms
- release id
- clinical-indications-draft-1
- disease state id
- ds-myeloproliferative-neoplasms
- nct id
- NCT00245037
- outcome key
- om-0000
- arm key
- OG000
- arm label
- Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)
- regimen
- Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0 Therapeutic allogeneic lymphocytes: A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species. Busulfan: Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative. IV Busulfan is available and diluted and administered per package insert guidelines. Cyclosporine: Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including
- analyzed count
- 147
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00245037-om-0000#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-myeloproliferative-neoplasms
- nct id
- NCT00245037
- outcome key
- om-0001
- arm key
- OG000
- arm label
- Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)
- regimen
- Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0 Therapeutic allogeneic lymphocytes: A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species. Busulfan: Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative. IV Busulfan is available and diluted and administered per package insert guidelines. Cyclosporine: Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including
- analyzed count
- 147
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00245037-om-0001#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-myeloproliferative-neoplasms
- nct id
- NCT00245037
- outcome key
- om-0002
- arm key
- OG000
- arm label
- Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)
- regimen
- Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0 Therapeutic allogeneic lymphocytes: A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species. Busulfan: Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative. IV Busulfan is available and diluted and administered per package insert guidelines. Cyclosporine: Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including
- analyzed count
- 147
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00245037-om-0002#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-myeloproliferative-neoplasms
- nct id
- NCT00245037
- outcome key
- om-0003
- arm key
- OG000
- arm label
- Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)
- regimen
- Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0 Therapeutic allogeneic lymphocytes: A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species. Busulfan: Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative. IV Busulfan is available and diluted and administered per package insert guidelines. Cyclosporine: Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including
- analyzed count
- 147
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00245037-om-0003#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-myeloproliferative-neoplasms
- nct id
- NCT00245037
- outcome key
- om-0004
- arm key
- OG000
- arm label
- Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)
- regimen
- Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0 Therapeutic allogeneic lymphocytes: A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species. Busulfan: Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative. IV Busulfan is available and diluted and administered per package insert guidelines. Cyclosporine: Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including
- analyzed count
- 147
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00245037-om-0004#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-myeloproliferative-neoplasms
- nct id
- NCT00245037
- outcome key
- om-0005
- arm key
- OG000
- arm label
- Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)
- regimen
- Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0 Therapeutic allogeneic lymphocytes: A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species. Busulfan: Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative. IV Busulfan is available and diluted and administered per package insert guidelines. Cyclosporine: Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including
- analyzed count
- 147
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00245037-om-0005#groups/OG000
- harms
- release id
- clinical-indications-draft-1
- disease state id
- ds-myeloproliferative-neoplasms
- nct id
- NCT00245037
- harm key
- EG000
- source section id
- NCT00245037-ae
- event group key
- EG000
- event group label
- Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)
- serious affected
- 59
- serious at risk
- 147
- other affected
- 52
- other at risk
- 147
- frequency threshold
- 0
- collection period
- Non-hematologic toxicities and adverse experiences ≥ Grade 3 will be assessed up to day +100 using the NCI Common Toxicity Criteria for Adverse Events v3.0 (CTCAE). Infections and GVHD will be assessed up to 5 years post transplant.
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- quality of life
- setting source links
Preserved source evidence · Not medical advice